CytomX Therapeutics, Inc. (CTMX) financial statements and ratios from SEC XBRL: revenue $0.0B (TTM), net margin -22.8%, revenue growth -44.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $76.20M |
| Revenue (TTM) | $0.0B |
| Net Margin | -22.8% |
| Operating Margin (TTM) | 579.0% |
| Revenue Growth (YoY) | -44.8% |
| FCF Growth (YoY) | -12.4% |
| Price / Book | 2.37 |
| Price / Sales | 25.62 |
| FCF Yield | -20.6% |
| Altman Z-Score | 0.58 (distress) |
| Industry P/E (Pharmaceutical Products) | 17.2 |
| Sector P/E (Healthcare) | 21.7 |
CTMX overview · CTMX earnings · CTMX KPIs · CTMX documents · CTMX ownership · CTMX peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.